Praxis Precision Medicines, Inc. ((PRAX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Praxis Precision Medicines, Inc. is conducting a clinical trial titled ‘A Seamless, Clinical Trial to Investigate the Safety and Efficacy of Multiple Doses of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy.’ The study aims to assess the safety and efficacy of PRAX-222 in children aged 2 to 18 years with this rare neurological condition, which could significantly impact treatment options for affected families.
The intervention being tested is PRAX-222, a drug designed to treat early onset SCN2A developmental and epileptic encephalopathy. The study involves multiple dosing strategies, including initial, ascending, and fixed doses, as well as placebo comparisons.
The study is interventional and employs a randomized, parallel design with both open-label and double-blind phases. It uses a quadruple masking approach to ensure unbiased results, with the primary goal of treatment evaluation.
The study began on February 10, 2023, with primary completion expected by August 15, 2025. The last update was submitted on August 15, 2025, indicating ongoing progress and data collection.
The outcome of this study could influence Praxis Precision Medicines’ stock performance by potentially enhancing its portfolio with a novel treatment for a rare condition. This could also affect investor sentiment positively, especially if results show significant efficacy and safety, positioning the company favorably against competitors in the neurological disorder treatment market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.